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SUMMARY 
 
 
Neuronal and glial cells require iron for DNA synthesis and 
mitochondrial respiration and as cofactor for enzymes involved in 
neurotransmitters synthesis and axon myelination (Chen et al., 1995; 
Connor and Menzies, 1996). In addition, free iron can promote the 
generation of reactive oxygen species via Haber Weiss-Fenton 
reactions thereby leading to lipid, protein and DNA damage 
(Halliwell and Gutteridge, 1990). The maintenance of iron 
homeostasis is mainly regulated by the transferrin receptor that 
transports iron into the cell  
(Fishman et al., 1987) and by ferritin that sequesters this metal 
(Harrison and Arosio, 1996). The level of ferritin is mainly regulated 
post-transcriptionally by interaction between the iron regulatory 
proteins IRP1 and IRP2 and a sequence located in the 5’ untranslated 
region of ferritin mRNA (iron responsive element, IRE). IRP1, the 
cytosolic counterpart of mitochondrial aconitase (Kennedy et al., 
1992), is a bifunctional protein that, through [4Fe-4S] cluster 
assembly/disassembly, switches from the aconitase form to the IRP1 
form in response to the intracellular iron level (Guo et al., 1994). IRP2,  
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homologous to IRP1, lacks the [4Fe-4S] cluster and its activity 
increases in iron-depleted cells by protein stabilization.  
Dysregulation of iron homeostasis coupled to oxidative stress occurs 
in several neurodegenerative disorders (Thompson et al., 2001; Ke 
and Ming Qian, 2003), as well as in ischemic brain injury ( Kondo et 
al., 1995; Dorrepaal et al., 1996). Furthermore, induction of ferritin 
immunoreactivity and activation of ferritin gene transcription has 
been shown in the brain during ischemia/reperfusion (Ishimaru et 
al., 1996; Chi et al., 2000).  
Given the susceptibility of cerebral cells to iron-induced oxidative 
stress, we investigated the intracellular mechanisms that control 
ferritin synthesis and ferritin's role as an iron-segregating protein in 
the cell's defense against hypoxia/reoxygenation-induced injury. We 
thus examined IRP RNA-binding activity, ferritin expression and 
biosynthesis in cortical neurons and glial cells exposed to oxygen 
and glucose deprivation (OGD1), and to OGD followed by 
reoxygenation. 
The results show that hypoxia decreases IRP1 binding activity in 
glial cells and enhances it in cortical neurons. These effects were 
reversed by reoxygenation in both cell types. In glial cells there was 
an early increase of ferritin synthesis during the hypoxia and 
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reoxygenation, and baseline level was reached within 24 hr. 
Conversely, in cortical neurons ferritin synthesis was stimulated only 
during the late phase of reoxygenation. Analysis of ferritin mRNA 
levels, suggests that ferritin synthesis in glial cells is regulated 
mainly post-transcriptionally by IRPs, while the late ferritin increase 
in neurons is IRPs-independent and seems to be transcriptionally 
regulated. The different regulation of ferritin expression may account 
for the different vulnerability of neurons and glial cells to the injury 
elicited by oxygen and glucose deprivation/reoxygenation. 
The greater vulnerability of cortical neurons to hypoxia-
reoxygenation was strongly attenuated by exogenous administration 
of ferritin during OGD/reoxygenation, suggesting the possible 
cytoprotective role exerted by this iron-segregating protein.  
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INTRODUCTION 
1. The importance of iron 
1.1 Iron: an essential but potentially toxic nutrient  
The chemical versatility of iron has made it one of the most 
commonly used metals in biological system. In vertebrates, multiple 
physiologiacal processes including oxygen transport, respiration, 
DNA synthesis, formation of some neurotransmitters and hormones, 
xenobiotics metabolism, and certain aspects of host defense use iron-
containing proteins. 
The essential role of iron in human and animal health became 
apparent with the identification of iron as body constituent and with 
the understanding of the relationship between adequate iron intake 
and the prevention of certain diseases (Neilands, 1991). Today, the 
nutritional importance of iron is clear, given the worldwide 
prevalence of physiological disorders arising from iron deficiency 
and the demonstration of the central role of iron-containing proteins 
in multiple cellular processes (Bothwell, 1995). However, when 
present at levels that  exceed the capacity of organism to safely use it, 
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iron can be toxic because of its ability to promote oxidation of lipids, 
proteins, and other cellular components. High levels of iron have 
been associated with increasedincidence of some cancers, 
dysfunction of organs, such as heart, pancreas, or liver and 
development of neurodegenerative disorders (Halliwell, 1992). 
 
1.2 Toxicity of iron 
The efficiency of Fe(II) as an electron donor and of Fe(III) as an 
electron acceptor is a fundamental feature for many biochemical 
reactions and renders this element an essential mineral and nutrient. 
However, this property turns iron into a potential biohazard, because 
under aerobic conditions, it can readily catalyze the generation of 
noxious radicals. Iron’s toxicity is largely based on Fenton and 
Haber-Weiss chemistry (Fig. 1A), where catalytic amounts of iron are 
sufficient to yield hydroxyl radicals (OH.) from superoxide (O2.-) and 
hydrogen peroxide (H2O2), collectively known as “reactive oxygen 
intermediates” (ROIs) (Halliwell and Gutteridge, 1990). Importantly,  
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A. 
 
  Fe(II) + H2O2 → Fe(III) + OH- + OH · (Fenton) 
 
  Fe(III) + O2·- → Fe(II) + O2 
 
  Net reaction: 
 
  H2O2  + O2·-  Fe→ OH- + OH· + O2 (Haber-Weiss) 
 
B. 
    
   Fe(II) + ROOH →  Fe(III) + OH· + RO· 
 
    Fe(III) + ROOH → Fe(II) + H+ + ROO· 
 
     RSH + OH· → RS· + H2O 
 
   RS· + O2 → ROO· 
 
C. 
 
   Heme-Fe(II)- O2 +  H2O2  → Heme- Fe (IV)- OH· + O2 + OH· 
 
     Heme- Fe (IV)- OH· + ROOH → Heme- Fe(III) + ROO· + H2O2   
 
D. 
 
   Fe(II) + H2O2 → Fe(II)-O + H2O 
 
   Fe(II) + O2  → [Fe(II)-O2 → Fe(III)- O2·-] → Fe(III) + O2·- 
 
 
 
 
Fig. 1. Iron and free radical 
(A) Iron-catalyzed generation of the hydroxyl radical via the Fenton 
reaction; the net Haber-Weiss reaction is also indicated. (B) Iron-catalyzed 
generation of organic radicals. (C) Heme-catalyzed generation of oxygen 
radicals via oxoferryl intermediates. (D) Direct interaction of iron with 
oxygen.  
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ROIs are inevitable byproducts of aerobic respiration and emerge by 
incomplete reduction of dioxygen in mitocondria. ROIs can also be 
generated during enzymatic reactions in other subcellular 
compartments, such as in peroxisomes, the endoplasmatic reticulum, 
or the cytoplasm. 
Redox active iron catalyzes the generation of not only hydroxyl 
radicals, but also of organic reactive species, such as peroxyl (ROO.), 
alkoxyl (RO.), thiyl (RS.), or thiyl-peroxyl (RSOO.) radicals (fig. 1B). 
Interestingly, heme iron may also catalyze the formation of radicals, 
mainly via formation of oxoferryl intermediates (Ryter and Tyrrell, 
2000) (fig. 1C). Finally, ferrous iron can also contribute as reactant, 
rather than as catalyst, to free radical generation by a direct 
interaction with oxygen, via ferryl (Fe 2+-O) or perferryl (Fe 2+-O2) 
iron intermediates. 
Free radicals are highly reactive species and may promote oxidation 
of proteins, peroxidation of membrane lipids, and modification of 
nucleic acids. An increase in the steady state levels of reactive oxygen 
species beyond the antioxidant capacity of the organism, called 
oxidative stress, is encountered in many pathological conditions, 
such as chronic inflammation, ischemia-reperfusion injury, or 
neurodegeneration (Ischiropoulos and Beckman, 2003). Excess of 
                                                                                                       
 
 16 
redox active iron aggravates oxidative stress and leads to accelerated 
tissue degeneration. This is evident in disorders of hereditary or 
secondary iron overload. Under physiological conditions, 
extracellular iron is exclusively bound to transferrin, a monomeric 
glycoprotein serving as the plasma iron carrier, which maintains iron 
soluble and non-toxic, unable to engage in Fenton/Haber-Weiss 
reactions (Ponka et al.,1998). In healthy individuals, only 30% of 
circulating transferrin binds to iron. In pathological iron overload, 
iron gradually saturates the iron-binding capacity of transferrin and 
forms redox-active, low-molecular-weight chelates. Non-transferrin-
bound iron eventually gets internalized into tissues by poorly 
defined mechanisms, resulting in cell damage and tissue injury. 
 
1.3 Iron in the brain 
Iron is the most abundant transition metal in the brain. It not only 
acts as cofactor for many heme and non-heme enzymes involved in 
cellular energy metabolism, but it also plays an essential role in 
many other metabolic processes including DNA and protein 
synthesis, formation of myelin and of dopamine and development of 
dendritic trees (Gerlach et al., 1994). In the brain, iron is most 
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abundant in the basal ganglia (at a concentration equivalent to that in 
the liver, the third most abundant source of iron in the body) (Beard 
et al., 1993). 
Iron is predominantly stored within oligodendrocytes, cells of the 
CNS that produce and maintain myelin. Indeed, iron-containing 
oligodendrocytes are found in satellite positions near large neurons 
where they regulate iron availability to neurons.  
The iron transport protein, transferrin (Tf), is also predominantly 
found in the oligodendrocytes, but additional locations include 
tanycytes, endothelial cells, choroids plexus, epithelial cells, and 
ependymal cells (Connor, 1994). It is notable that iron and Tf are not 
distributed identically in the brain because Tf are not the main 
storage form of iron. Ferritin (Fr), a multimeric protein that binds up 
to 4500 atoms, is the major storage form of iron. Indeed, there is 10 
times more ferritin than transferrin in the cerebral cortex. About one-
third of brain iron is stored in ferritin in the ferric form (Fe 3+), which 
is also predominantly distributed in glial cells, particularly in 
microglia and oligodendrocytes (Morris et al., 1992). It is evident that 
oligodendrocytes play an important role in maintaining iron 
homeostasis in the brain. 
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1.4 Mechanisms of iron transport in the brain 
The mechanisms of iron transport across the blood-brain-barrier 
(BBB) have not yet been completely clarified. Evidences suggests that 
the transferrin-transferrin receptor (Tf-TfR) pathway might be the 
major route of iron transport across the luminal membrane of the 
capillary endothelium (Malecki et al., 1999), and that iron, possibly in 
the form of Fe2+, crosses the abluminal membrane and enters the 
interstitial fluid(IF). However, the molecular events of this process 
are not known. Evidence shows that the uptake of Tf-bound iron (Tf-
Fe) by TfR-mediated endocytosis from the blood into the cerebral 
endothelial cells is no different from uptake into other cells types 
(Bradbury, 1997). This processes includes several steps: binding, 
endocytosis, acidification and dissociation, then translocation of the 
iron across the endosomal membrane,  by a processes mediated by 
divalent metal transporter 1 (DMT1) (Burdo et al., 2001). Most of the 
Tf will return to the luminal membrane with TfR, whereas the iron 
crosses the abluminal membrane by undetermined mechanism (fig. 
2). Recent studies have shown that ferroportin 1-hephaestin (FP1-
Hp) and/or Hp-independent iron export sistems might play a key 
role in Fe2+ transport across the basal membrane of enterocytes in the  
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Fig. 2. Proposed scheme for iron transport across the BBB  
The Tf-TfR pathway might be the major route of iron transport across 
the luminal membrane of the BBB. Tf-Fe uptake by endothelial cells 
is similar in nature to the uptake into other cell types (green arrows). 
Iron (Fe2+) probably crosses the abluminal membrane via FP1-Hp 
and/or independent export system (light blue arrows). Lfr-Lf and 
GPI-anchored p67-secreted-p97 pathway might also be involved in 
iron transport across the BBB (dark blue arrows). 
Abbreviations: BBB, brain-blood barrier; Cp, ceruloplasmin; DMT1, 
divalent metal transporter; FP1, ferroportin 1; GPI-p97, GPI-
anchored p97; Hp, hephastin; Lf, lactoferrin; LfR, lactoferrin receptor; 
NTBI, non-transferrin-bound iron; Tf-Fe, transferrin-bound iron; Tf, 
transferrin; TfR, transferrin receptor. 
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gut (Donovan et al., 2000; Vulpe et al., 1999), but it is unknown if 
these two systems have the same role in Fe 2+ transport across the 
abluminal membrane of BBB. 
Another proposed mechanism of Fe2+ transport across abluminal 
membrane involves astrocytes that probably have the ability to take 
up Fe2+ from endothelial cells (Oshiro et al., 2000). In addition to the 
Tf-TfR pathway, it has been suggested that the lactoferrin receptor-
lactoferrin (LfR-Lf) and glycosylphosphatidylinositol (GPI)-anchored 
p97-secreted p97 pathways might also play a role in iron transport 
across the BBB (Faucheux et al., 1995). It is also possible that a small 
amount of iron might cross the BBB in the form of intact Tf-Fe 
complex by receptor-mediated transcytosis (Moos et al., 1998) (fig. 2). 
After the transport across the BBB the iron binds quickly to Tf that is 
secreted from oligodendrocytes and epithelial cells of the choroids 
plexus (Moos et al., 1998) (fig.3). Because the affinity of Tf with iron is 
higher than that of the other iron transporters, Fe 3+ in CSF and IF 
will bind to Tf first. Unlike Tf in blood, Tf in CSF and IF is fully 
saturated with iron and the excess of iron will bind to other 
transporters. Hence, it is possible that there are two transport forms  
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Fig. 3. Proposed scheme for iron transport in the brain  
There are two transport forms of iron in the brain: Tf-Fe and NTBI. Tf-Fe is 
taken up by neurons via a TfR-mediated (blue arrows). NTBI, including Lf-
Fe3+ and S-p97- Fe3+, is acquired by neurons probably via DMT1- and TCT-
mediated (purple arrows) processes or LfR and GPI-p97-mediated 
processes (black arrows). The molecular mechanism underlying these 
processes are unknown.  
Abbreviations: DMT1, divalent metal transporter; GPI-p97, GPI-anchored 
p97; LfR, lactoferrin receptor; NTBI, non-transferrin-bound iron; S-p97, 
secreted p97; TCT, trivalent cation-specific transporter; Tf-Fe, transferrin-
bound iron; Tf-Fe, transferrin-bound iron; Tf-TfR, transferrin-transferrin 
receptor. 
 
                                                                                                       
 
 22 
of iron in the CSF and IF in the brain: Tf-Fe and non-Tf-bound iron 
(NTBI) (Moos et al., 1998). The latter probably includes citrate- Fe3+, 
ascorbate- Fe 2+ and albumin-Fe (2+ or 3+), as well as Lf- Fe 3+ and 
secreted p-97- Fe 3+. 
Tf-Fe, or probably Lf-Fe, and secreted p97-Fe will be taken up by 
brain cells via TfR- or Lfr- and GPI-anchored p-97-mediated 
processes, respectively (Malecki et al., 1999). NTBI will be acquired 
by neuronal cells or other brain cells, probably via DMT-1- or 
trivalent cation-specific transporter (TCT)-mediated mechanism. 
 
1.5 Cellular iron uptake  
Transferrin receptor provides for controlled access of transferrin to 
cells (fig.4). Two such receptors have been described. The first and 
much more studied of these is now known as transferrin receptor 1 
(TfR1). Consisted of two disulfide-bonded identical 90 KDa subunits, 
each bearing three asparagines-linked and one threonine-linked 
carbohydrate chains, TfR is expressed by all iron-requiring cells, and 
is far more abundant than transferrin receptor 2 (TfR2). The first 61 
amino acids of each subunit form the cytoplasmatic domain, and 
lead to a membrane-anchoring hydrophobic sequence of residues 62- 
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Fig. 4. The Tf cycle 
Holotransferrin (HOLO-Tf) binds to the transferrin receptor (TfR) at the cell 
surface. These complexes localize to clathrin-coated pits, which invaginate 
to initiate endocytosis. Specialized endosomes form, which are acidified by 
a proton pump. When the required acidic pH is reached, iron is released 
from transferrin (Tf) and is co-transported, with the protons, out of the 
endosomes by the divalent cation transporter DCT1. Apotransferrin (APO-
TF) is returned to the cell membrane bound to TfR, where, at neutral pH, 
they dissociate to participate in further rounds of iron delivery. The iron can 
be targeted to the mitochondria. In non-erythroid cells, iron is stored in the 
form of ferritin and haemosiderin. 
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89 that spans the lipid bilayer once. The remainder of the protein, 
bearing the transferrin recognition sites, lies in the exocytic region. 
TfR2, described in 1999, exists in two forms. The first of these, TfR2-
α, has 45% sequence identity and 66% similarity to TfR1, while the 
second, TfR2-β, lacks the N-terminal portion, including the 
cytoplasmic and transmembrane regions. Expression of TfR2 is 
predominantly in liver and liver-derived cell lines, but also in human 
erythroleukemic K562 cells.  
Tf binds to the TfR at the cell surface and is internalized though 
clathrin-coated pits into endosomes via a well characterized pathway 
(fig. 4). At the acidic pH of the endosome, iron dissociates from Tf 
and is taken to the cytoplasm, presumably via a membrane 
transporter. The rate of iron release from Tf to cells depends on the 
pH of the endosome and its association with the TfR (Sipe et al., 
1991), but the efficiency is probably less than 100%. Endosomal pH 
varies with cell type, ranging from 6 to 5.5. Even the lowest pH 
achieved by endosomes, however, is not sufficient to remove iron 
from transferrin in the few minutes taken by the transferrin cycle, so 
that other mechanisms must participate in iron release. Such 
mechanisms might include the availability of iron-sequestering 
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molecules such as citrate or ATP, or the reduction of iron in the 
transferrin-transferrin receptor complex, as suggested by recent 
identification of a membrane ferrireductase (McKie et al., 2001). 
Further characterization of the trafficking of ferrireductase is needed 
to explore this possibility. After the return of the receptor Tf complex 
to the cell surface, the extracellular pH triggers the release of apo-Tf, 
allowing another round of binding and endocytosis to begin.  
The transferrin/TfR1 pathway defines the major route for cellular 
iron uptake and some cell types (for example erytroid cells) depend 
on it for iron acquisition. The targeted disruption of mouse TfR1 has 
been associated with early embryonic lethality due to defective 
erythropoiesis (Levy et al., 1999). Transferrin receptor 2 (TfR2), an 
homologue of TfR1, cannot compensate for TfR1 deficiency and 
rescue the embryonic lethal phenotype of TfR1 -/-. The defect in TfR1 
-/- embryos is restricted within the erythroid and neuronal tissue 
(Levy et al., 1999), suggesting that alternative pathway for cellular 
iron acquisition in other types exist. For example, new pathway for 
the delivery of iron into cells via enterobactin and the neutrophil-
derived protein neutral gelatinase-associated lipocalin (NGAL) has 
recently been described (Goetz et al., 2002; Yang et al., 2002). 
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Enterobactin belongs to a class of low-molecular-weight iron-
chelating metabolites known as siderophores, which are synthesized 
by some bacteria and fungi to scavenge extracellular iron. It is not 
clear whether mammals can produce siderophores themselves, but 
the above data suggest that they can utilize siderophore-based 
mechanisms for iron acquisition.  
 
1.6 Cellular iron use 
Once iron has entered the cytosol, little is know about how it is 
shuttled to the various intracellular proteins and organelles that need 
iron. Generally, there are three possible fates for iron in the 
cytoplasm: a) it is used for the synthesis of iron-containing proteins; 
b) it is stored; or c) it is exported from the cells. The extent to which 
iron delivered to the cytoplasm is then directed, along metabolic 
pathways, rather then being incorporated into the iron storage 
proteins, likely depends on the amount of iron taken up, as well as 
the iron status and metabolic needs of the cells. One critical location 
of intracellular iron use is the mitochondrion. This organelle is the 
site of iron incorporation into protoporphyrin IX to form heme, as 
well as the location where metal centers for heme and/or non heme 
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are assembled and inserted into proteins required for mitochondrial 
function. In liver and in erythroid cells, a large fraction of iron is 
used for heme formation that is modulated by coordinating the 
synthesis of protoporphyrin IX with the availability of iron (Ponka et 
al., 1997). The rate-limiting enzyme for heme formation is 5-
aminolevulinate synthase (eALAS). Control of eALAS synthesis is a 
key factor in modulating heme formation by erythroid and non-
erythroid cells.  Much remains to be understood concerning the 
formation of iron centers in mitochondria and the transport of iron to 
the intracellular sites where non-heme iron-proteins are assembled. 
Recent works in yeast and humans, in relation to the disease 
Friedrich’s ataxia, have indicated that mitochondria have a dynamic 
non-protein-bound, non-heme iron pool that functionally interacts 
with the cytosolic iron pool (Knight et al., 1998). These and other 
works have identified components of mitochondrial iron uptake and 
efflux pathways (Allikmets et al., 1999; Lange et al., 1999). 
 Moreover iron is an essential cofactor for many proteins involved in 
normal function of neuronal tissue, such as the non- haem iron 
enzyme tyrosine hydroxylase, which is required for dopamine 
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synthesis.  The oligodendrocytes use high level of iron because they 
are responsible for myelin production and maintenance.  
In addition to controlling the flow of iron towards metabolic use, an 
important component of the means for establishing iron homeostasis 
is through alterations in iron storage capacity. Modulation of iron 
storage can occur through changes in synthesis and, in some cases, 
degradation of ferritin.    
Recently, it has become evident that numerous cell types express the 
iron exporter ferroportin/Ireg1/MTP1 (McKie et al., 2000;  Abbound 
et al., 2000). Recent studies on the relationship between iron and 
copper metabolism have shown that copper deficiency leads to an 
accumulation of iron in several tissues (Eisenstein, 2000). Depending 
on the tissue, the multicopper oxidases ceruloplasmin and 
hephaestin may have critical roles in iron export. 
By regulating the expression of the TfR, ferritin, and the ferrous iron 
exporter, cells have many mechanism for preventing accumulation of 
excess iron. 
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1.7 Ferritin structure and function 
Ferritin  is a ubiquitous and highly conserved iron-binding protein. 
In vertebrates, the cytosolic form consists of 2 subunits, termed H 
and L. Twenty-four ferritin subunits assemble to form the apoferritin 
shell (fig. 5). Each apoferritin molecule of 450 KDa can sequester up 
to approximately 4500 iron atoms (Harrison et al., 1996). Depending 
on the tissue type and physiologic status of the cell, ratio of H to L 
subunits in ferritin can vary widely, from predominantly L in such 
tissues as liver and spleen, to predominantly H in heart and kidney 
(Arosio et al., 1976). The H to L ratio is not fixed, but is rather quite 
plastic: it is readily modified in many inflammatory and infectious 
conditions, and in response to xenobiotic stress, differentiation, and 
developmental transitions, as well as other stimuli. Ferritin H and L 
subunits are encoded by separate genes. Although a single functional  
mitochondrial ferritin gene has recently been described (Levi et al., 
2001). Multiple pseudogenes are also present. Ferritin also has 
enzymatic properties, converting Fe (II) to Fe (III) as iron is 
internalized and sequestered in the ferritin mineral core. Use of  
recombinant ferritins has demonstrated that this function is an  
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Fig. 5. Ferritin structure 
Twenty-four ferritin subunits assemble to form the apoferritin shell, that 
has a molecular weight of  ~ 450  KDa.               
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inherent feature of the H subunit of ferritin, which has a ferroxidase 
activity (Lawson et al., 1989). The ferroxidase center is evolutionarily 
conserved, and ferroxidase activity is dramatically reduced following 
mutation of residues His65 and Glu62 in both human and mouse 
(Rucker et al., 1996).  
Small quantities of ferritin are present in human serum, and are 
elevated in conditions of iron overload and inflammation (Torti et al., 
1994). Serum ferritin is iron-poor, resembles ferritin L 
immunologically, and may contain a novel “G” (glycosylated) 
subunit (Santambrogio et al., 1987). Despite  widespread use of 
serum ferritin as clinical indicator of body iron stores, little is known 
of source of this ferritin. 
The critical role of ferritin in cellular iron homeostasis is intimately 
linked to its primary and best-studied function of iron sequestration. 
The toxicity of iron in cellular systems is attributable in large part to 
its capacity to participate in the generation of reactive species, which 
can directly damage DNA, lipids, and proteins, leading to profound 
cellular toxicity. In the organism iron balance is maintained with 
exquisite care. Ferritin, by capturing and “buffering” the intracellular 
labile pool (Kakhlon et al., 2001; Picard et al., 1998) plays a key role in 
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maintaining iron homeostasis. It is not surprising, then, that 
homozygous murine knockouts of ferritin H are lethal (Ferreira et al., 
2000). Recently, it has become evident that regulatory factors, in 
addition to those that regulate iron flux, have important impact on 
cellular ferritin. In fact, ferritin can be viewed not only as part of a 
group of iron regulatory proteins that include transferrin and 
transferrin receptor, but also as a member of protein family that 
orchestrates the cellular defense against stress and inflammation 
(Torti et al., 1988). 
 
1.8 Ferritin in the brain   
Ferritin has classically been known as an iron storage protein in 
many types of cells, including those of the brain. The cellular and 
regional distribution of ferritin in brain has been discussed (Benkovic 
and Connor, 1993). Recent reports have indicated the presence a 
ferritin receptor in the brain that is predominantly expressed in 
white matter (Hulet et al., 1999a). This distribution indicates the 
presence of two, non-overlapping receptor system for iron in the 
brain, as transferrin receptors are mainly located in grey matter 
regions of the brain. 
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The selective expression of a ferritin receptor on the myelin 
producing cells, oligodendrocytes, indicates these cells have 
developed their own iron uptake system (Hulet et al., 2000). It is well 
established that iron acquisition by oligodendrocytes is essential for 
normal production of myelin. Hypomyelination is a consistent and 
predominant effect of iron deficiency in humans and animal models 
(Pinero and Connor, 2000) and ferritin receptor expression in myelin 
tracts is altered in Multiple Sclerosis (Hulet et al., 1999b). 
The expression of a ferritin receptor ensures that oligodendrocytes 
do not have to compete for Tf delivered iron in the brain and also 
provides these cells with the opportunity to acquire much more than 
could be delivered by Tf. The uptake of ferritin into oligodendrocytes 
is ATP and clathrin dependent (Hulet et al., 2000). Alterations in 
ferritin levels in brain could influence iron delivery to the 
oligodendrocytes. Too little iron via ferritin could promote 
demyelination but also, elevated ferritin could be a source of iron for 
inducing iron mediated oxidative injury. Ferritin is present in the 
CSF and thus could be expected to access the interstitial fluid in the 
brain. The levels of CSF ferritin are roughly 10% of levels of ferritin 
found in the serum. Normal CSF contains approximately 3 ng/ml, 
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but this concentration will increase during infectious 
meningoencephalitis, CNS vascular diseases and dementia without 
vascular pathology (Sindic et al., 1981). Marked elevations of CSF 
ferritin (30-fold) were observed in patients with bacterial or fungal 
meningitis in contrast to modest CSF ferritin elevations in patients 
with viral meningitis. Ferritin is also elevated in the cerebral spinal 
fluid of Multiple Sclerosis patients (Le Vine et al., 1999). 
Consequently, CSF ferritin could be a early valuable clinical tool for 
differential diagnosis (Campbell et al., 1986). In contrast to serum 
ferritin, which is highly glycosylated (>70%), ferritin within the CSF 
is largely non-glycosylated (<20%). Non-glycosylated ferritin is 
usually considered as “tissue ferritin” suggesting that CSF ferritin is 
derived from cell death and subsequent release (Zappone et al., 
1986). However, the concentration of ferritin within the CSF of 
normal patients is significantly higher than which would be expected 
to occur by passive diffusion across the blood-CSF barrier (Keir et al., 
1993). This suggest that local synthesis and secretion of ferritin by 
brain cells occurs normally.  
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2 . Cytoplasmatic control of ferritin synthesis 
2.1 Iron-mediated regulation ferritin 
Not only does ferritin sequester iron in a nontoxic form, but levels of 
“labile” iron regulate cellular ferritin levels, protecting cells from 
damage triggered by excess iron. The content of cytoplasmatic 
ferritin is regulated by the translation of ferritin H and L mRNAs in 
response to an intracellular pool of “ chelatable” or “labile iron” 
(Konijn et al., 1999). Thus, when iron levels are low, ferritin synthesis 
is decreased; conversely, when iron levels are high, ferritin synthesis 
increases. Although in certain circumstances there is an increase in 
ferritin mRNA in response to iron, the regulatory response of ferritin 
to iron is largely post-transcriptional, and due to the recruitment of 
stored RNA from monosomes to polysomes in the presence of iron. 
This process is mediated by interaction between RNA binding 
proteins and a sequence in the 5’ untranslated region of H and L 
ferritin mRNA termed iron responsive element (IRE) that has a 
“stem-loop” secondary structure (fig. 6). There are two RNA binding 
proteins, iron regulatory proteins 1 and 2 (IRP1 and IRP2), that bind 
to this stem loop structure and inhibit RNA translation. These 
proteins are regulated differently: IRP1 is an iron-sul
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protein that exists in 2 forms. When iron is abundant, it exists as a 
cytosolic aconitase. When iron is scarce, it assumes an open 
configuration associated with the loss of iron atoms in the iron-sulfur 
cluster, and can bind the IRE stem loop, acting as a repressor of 
ferritin translation (fig. 7). In contrast, IRP2 is regulated by its 
degradation: IRP2 protein is abundant in iron insufficiency, but is 
degraded rapidly in iron excess through targeting of a unique 73 
amino acid sequence (Iwai et al., 1998) (fig. 7). 
 
2.2 IRP1 and IRP2 
The molecular cloning of IRP-1 offered insights into the 
structural/functional correlation that allows it to undergo changes in activity 
and function with no appreciable variations in protein content. In fact, this 
evolutionarily conserved (Andersen et al., 1998) 98 kDa protein coded in 
human chromosome 9 (Rouault et al., 1990) is highly homologous 
with mitochondrial (m-)aconitase, which converts citrate into 
isocitrate in the tricarboxylic acid cycle, with 100% identity of the 
amino acids involved in the formation of catalytic core (Beinert et al., 
1993). 
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Fig. 6. Homeostatic responses to iron supply mediated by IRE-IRPs 
interactions.  
Decreased iron supply activates binding of IRPs to IRE, resulting in 
translational inhibition of the mRNAs encoding ferritin (H and L chains). 
Conversely, IRPs do not bind to cognate IREs in iron-replete cells, 
permitting translation of ferritin. 
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Fig. 7. IRPs regulation by iron and other stimuli 
A) Post-translational regulation of bifunctional IRP1 in response to iron and 
other stimuli via iron-sulfur cluster switch. 
B) Iron-dependent degradation of IRP2 by a mechanism involving 2-
oxoglutarate-dependent oxygenases. 
 
 
A 
B 
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The abundance of information concerning the biochemistry and 
structure of m-aconitase has allowed the construction of an IRP-1 
model that implies a post-translational switch between an apoprotein 
form capable of binding iron-responsive-element (IRE) motifs and an 
enzymically active holoprotein endowed with 4Fe-4S cluster 
(Eisenstein et al., 1998). In the holoprotein, the four domains are in 
closed conformation and permit the assembly of a 4Fe-4S cubane 
cluster co-ordinated by cysteine residues. By contrast, as result of 
cluster disassembly, the apoprotein can accommodate the RNA in a 
cleft between domains 1-3 and 4. The switch between these two 
mutually exclusive functions of IRP1 is regulated by intracellular 
iron levels, because a high degree of aconitase activity is present 
under conditions of iron overload and full IRE-binding capacity 
exists in iron-depleted cells. The mechanism underlying the insertion 
and removal of cluster, and hence the conversion between the two 
functions of IRP1, remain poorly defined. 
Although two IRE-binding proteins were initially detected by RNA 
bandshift assays in rat cells, IRP2 was initially detected and 
characterized only several years after IRP1, probably because it is 
                                                                                                       
 
 40 
usually less abundant and can be electrophoretically distinguished 
from IRP1 only in murine cell extracts. IRP2 is highly homologous 
with IRP1, but has two major differences: the presence of a 73-amino-
acid insertion in the N-terminus and lack of aconitase activity (Cairo 
et al., 2000). The IRP2 specific sequence mediates the characteristic 
way by which this protein is regulated: in presence of  high iron 
levels, IRP2 is rapidly targeted to proteasome-mediated degradation 
(Iwai et al., 1998), and it has also been claimed that heme, rather than 
free iron, is involved in IRP2 degradation (Goessling et al., 1998) (fig. 
7).  Although both IRP1 and IRP2 bind the IRE and exert an 
inhibitory effect on ferritin synthesis, there are evidences that IRP1 
and IRP2 may have distinct tissue-specific role (Eisenstein, 2000). 
Thus , IRP2 knockout mice exhibit a pronounced misregulation of 
iron metabolism in the intestinal mucosa and central nervous system 
(LaVaute et al., 2001). The iron overload in specific areas of the brain 
was associated with the development of a progressive 
neurodegeneration. These data estabilish IRP2 as an important 
regulator of systemic iron metabolism. 
 Further, relative ratios of IRP1/IRP2 differ in a tissue-specific 
fashion, with IRP1 being more abundant than IRP2 in liver, kidney, 
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intestine, and brain, and less abundant in pituitary and pro-B-
lymphocytic cell line (Thomson et al., 1999). 
 
2.3 IRP regulation by stimuli other than iron 
IRPs were initially appreciated as intracellular iron sensors, but it 
soon became clear that they also respond to other stimuli. Exposure 
of cells to hydrogen peroxide (H2O2) or nitric oxide (NO) promotes 
removal of IRP1cluster and thereby induces IRE-binding activity (fig. 
7). The mechanism for cluster removal is not straightforward. While 
the cluster of IRP1 is generally sensitive to inactivation by reactive 
oxygen and nitrogen species (Cairo et al., 2002), which is reflected in 
loss of aconitase activity, this is not always associated with activation 
of IRE binding, which requires complete cluster disassembly. Thus, 
the superoxide anion (O2.-) or peroxynitrite (NOO.) readily 
diminishes the aconitase activity of IRP1, but fails to convert it into 
an IRE-binding protein (Soum et al., 2003). The response of IRP1 to 
H2O2 and NO are more complex. The H2O2-mediated conversion of 
IRP1 from cytosolic aconitase to IRE-binding protein is a result of 
signalling pathway rather than of direct chemical modification of the 
4Fe-4S cluster by H2O2. First all, IRP1 activation takes place when 
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intact cells, but not cell extract, are exposed to H2O2 (Pantopoulos 
and Hentze; 1995). By contrast, the treatment of purified 4Fe-4S IRP1 
with H2O2 yields 3FE-4S IRP1, which fails to bind to IREs 
(Brazzolotto et al., 1999). Importantly, the pathway for H2O2-
mediated activation of IRP1 is biphasic and can only be reconstitued 
in vitro in the presence of the particulate fraction of permeabilized  
cells (Pantopoulos and Hentze; 1995). The latter suggests the 
involvement of insoluble membrane-associated factors in the 
pathway. 
The mechanism for IRP1 activation by NO is distinct. Exposure of 
purified IRP1 to NO in vitro was recently shown to activate IRE 
binding (Soum et al., 2003), even though in earlier literature this 
effect was only partial. The kinetics of IRP1 activation upon exposure 
of Ltk- fibroblasts to S-nitroso-N-acetyl-D,L-penicillamine (SNAP), a 
donor of NO , and desferrioxamine, an iron chelator, show 
remarkable similarities (Pantopoulos and Hentze; 1996). Thus, IRP1 
activation requires at least 4h of continuous treatment with these 
drugs, while the “stress activation” of IRP1 is triggered by a transient 
pulse with H2O2 and occurs within 30-60 min. Moreover, SNAP and 
desferrioxamine also elicit the activation of IRP2, which does not 
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contain an aconitase-type cluster. These findings are compatible with 
model, according to which NO may modulate the LIP and thereby 
promote responses to iron deficiency. It is also conceivable  that a 
direct, NO-mediated cluster destabilization of IRP1 also accounts at 
least for a partial activation of IRE binding in vivo. 
 
3. Hypoxia 
Hypoxia is oxygen starving at the tissue and cellular levels. It is 
caused by reduction of oxygen supply in blood physiological levels. 
Severe hypoxia can result in anoxia, a complete loss of oxygen to an 
area of tissue. There are four major types of hypoxia. The first type, 
hypoxic hypoxia, is decrease of fraction of inhaled oxygen possibly 
due to hyperventilation from respiratory depression or altitude 
above sea level. The second type of hypoxia is termed anaemic 
hypoxia, and is characterized by a decrease in the amount of 
haemoglobin that binds oxygen in the blood. This can be caused by 
multiple factors, including but not limited to: blood loss, reduced red 
blood cell production, carbon monoxide poisoning, and a genetic 
defect of haemoglobin. Stagnant hypoxia, the third type of hypoxia 
that has been defined, results in low blood flow and is caused by 
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vasoconstriction and/or heart failure. The fourth type of hypoxia is 
hystotoxic hypoxia, a poisoning of oxidative enzymes that causes 
vasodilatation in brain arteries and veins, resulting in more blood 
flow to the brain tissues. This response is probably mediated by 
nitric oxide (NO) and adenosine. Hypoxia is a fundamental 
angiogenic stimulus. An important mediator of this primary 
stimulus is hypoxia-inducible TOR-1α (HIF-1α) (Wang et al, 1995). 
Normally, this protein is oxidized, ubiquitinylated and degraded in 
the proteasome. In the absence of oxygen, HIF-1α levels increase and 
stimulate VEGF transcription. Cells of the innate immune and in 
tissues below system get energy almost entirely from glycolysis, 
enabling survival under a variety of harsh conditions. In a recent 
report HIF-1α is now placed at the center of metabolic control in 
these cells (Cramer et al., 2003). The regulation of most proteins 
required for hypoxic adaptation occurs at the gene level and involves 
transcriptional induction via the binding of a transcription factor, 
hypoxia-inducible factor-1 (HIF-1), to the conserved sequence, 5-
(A/T)CGTG-3, in the hypoxia response element (HRE) on the 
regulated genes (Semenza et al., 1997). To date, about 100 hypoxia-
inducible genes have been found to be directly regulated by HIF-1. 
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HIF-1 is a heterodimer composed of 120 kDa HIF-1α subunit and a 
91-94 kDa HIF-1β subunit, both of which are members of basic helix-
loop-helix (bHLH)-PAS family. PAS is an acronym for the three 
members first recognised (Per, ARNT, and Sim). According, HIF-1α 
and HIF-1β each contain a bHLH domain near the N-terminus 
preceding the PAS domain. Whereas the basic domain is essential for 
DNA binding, the HLH domain and N-terminal half of the PAS 
domain are necessary for heterodimerization and DNA binding. 
Moreover, there are two transcriptional activation domains (TADs) 
in HIF-1α, the N-terminal activation domain (TAD-N), and the C-
terminal activation domain 
(TAD-C). In contrast, HIF-1β contains only one transcriptional 
activation domain at C-terminus. Furthermore, HIF-1α possess a 
unique oxygen-dependent degradation domain (ODD) that controls 
protein stability. In addition to the ubiquitous HIF-1α, the HIF-1α 
family contains two other members, HIF-2α (also called EPAS, MOPS 
or HLF) (Tian et al., 1997; Hogenesch et al., 1997; Ema et al., 1997)  and 
HIF-3α (Gu et al., 1998), both of which have more restricted tissue 
expression (Wenger et al., 2002). HIF-2α and HIF-3α contain domains 
similar to those in HIF-1α and exhibit similar biochemical properties, 
such as heterodimerization with HIF-1β and DNA binding to the 
                                                                                                       
 
 46 
same DNA sequence in vitro. HIF-2α is also tightly regulated by 
oxygen tension and its complex with HIF-1β appears to be directly 
involved in hypoxic gene regulation, as is HIF-1α (Wiesener et al., 
1998). However, although HIF-3α is homologous to HIF-1α, it might 
be a negative regulator of hypoxia-inducible gene expression (Hara 
et al., 2001). To active transcription, HIF-1α must recruit the 
transcriptional adapter/histone acetyltransferase proteins, p300 and 
CBP to the target gene promoters. This occurs by direct physical 
interactions between the transactivation domain (TAD) of HIF-1α 
and the first cysteine-histidine (CH1) domain of the p300/CBP 
complex. This domain of p300/CBP also binds member of the CITED 
(CBP /p300 interacting transactivator with ED-rich tail) family of 
transcription factors. CITED2 and CITED4 disrupt the interaction 
between HIF-1α and p300 and inhibit transactivation by HIF-1α and 
gene activation by hypoxia. 
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3.1 Regulation of HIF-1 
    3.1.1 Oxygen-dependent 
At normal oxygen levels, HIF-1 prolyl-hydrolases hydroxylate the 
prolyl residues at Pro 402 and 564 of the HIF-1α ODD. Furthermore, 
the asparagine hydroxylase FIH-1 (factor inhibiting HIF-1) 
hydroxylates Asp 803 of the HIF-1α C-terminal transactivation 
domain. The hydroxylated peptide interacts with an E3 ubiquitin-
protein ligase complex. After being poly-ubiquitinezed, HIF-1α is 
degraded by the 26S proteosome. Uder hypoxic conditions, HIF-1α is 
not hydroxylated because the major substrate, dioxygen, is not 
available. The unmodified protein escapes the VHL-binding, 
ubiquitination and degradation, and then dimerizes HIF-1β. The 
heterodimeric HIFs upregulate a myriad of hypoxia-inducible genes, 
triggering physiologic responses to hypoxia. Interestingly, PHD-1 
and –2 are inducible by hypoxia, indicating a feedback loop to avoid 
nuclear HIF-1 accumulation. 
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 3.1.2 Oxygen-independent 
In addition to mediating adaptation to hypoxia, HIF-1 also 
contributes to other cellular processes that occur under normoxic 
conditions, such as the development of normal tissues or tumors, the 
determination of cell death or survival, immune responses and the 
adaption to mechanical stress. Under normoxic conditions HIF-1 can 
be activated by various cytokines, growth factors, transition metals, 
iron chelation (inhibits enzymatic activity), as well as nitric oxide 
(NO). Degradation of HIF-1 in a VHL- and oxygen-independent 
manner is mediated by p53. Dephosphorylated HIF1α binds to p53 
while phosphorylated HIF-1α is the major form that binds to HIF-1β 
(Fox et al., 2004). HIF-1α protects p53 degradation by binding to 
Mdm2, the principal cellular antagonist of p52 (Chen et al., 2003). 
Also, inhibition of PI3K or mTOR prevent growth factor- and 
cytokine-induced HIF-1α accumulation. Generally HIF-1α induction 
by hypoxia is far greater than by growth factors and cytokines. The 
COP9 subunit CSN5 is able to stabilize HIF-1α in a pVHL-
independent form aerobically by inhibiting HIF-1α prolyl-564 
hydroxylation (Bemis et al., 2004). 
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3.2 Hypoxia-mediated iron regulation 
The link between hypoxia and iron has strengthened with the 
evidence of hypoxic regulation of proteins that regulate iron 
homeostasis. Indeed, all the major genes of iron metabolism respond 
to hypoxia. First, it has been shown that hypoxia or CoCl2 (which 
mimics hypoxia), results in a three-fold increase in TfR RNA, despite 
a decrease of IRP1 activity (Tacchini et al., 1999). Demonstration of a 
HIF-1 binding site in the TfR promoter suggests that the observed 
increase in TfR RNA results from hypoxia-induced stabilization of 
HIF-1 and increased transcription of the TfR gene rather than a 
change in TfR mRNA stability (Tacchini et al., 1999). Second, serum 
transferrin (Tf) levels increase in animals exposed to hypoxia 
(Simpson et al., 1996) and hypoxia increases Tf gene expression in 
hepatoma cells (Rolfs et al., 1997). Tf is also a member of the HIF-1-
regulated gene family (Bolann and Ulvik,1987) (fig. 8). Finally, as 
noted above, the activities of the RNA-binding proteins, IRP-1 and 
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IRP-2 are also regulated by hypoxia. Hypoxia exposure decreases 
IRP1-RNA binding activity and increases IRP2-RNA binding activity. 
The hypoxic increase in IRP2-RNA binding results from increased 
IRP2 protein levels (Hanson et al., 1999). Hypoxia stabilizes the [4Fe-
4S] active form of IRP1 at the expense of its RNA-binding activity 
(Hanson and Leibold, 1998). Indeed, it appears that, IRP2 plays a 
more critical role than IRP1 (Hanson et al, 1999).  
 
3.3 Ferritin regulation during hypoxia-ischemia 
Tissue ischemia and cellular hypoxia have been studied in a number 
of conditions and changes in ferritin documented. Hypoxia in 
neonatal rat oligodendrocytes and human oligodendrogliomas 
induced the synthesis of ferritin. This effect was not inhibited by 
actimonycin D, nor did RNA levels of ferritin H RNA change. The 
effects on ferritin in oligodendrocytes was recapitulated by 
exogenous iron and blocked by desferrioxamine (Qi et al., 1995). 
Similar effects on ferritin induction were observed in a rat model of 
acute hypoxic/ischemic insult. Shortly, after the hypoxic-ischemic 
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insult, ferritin-positive microglia accumulate in subcortical white 
matter. In addition, the ratio of H to L ferritins shifts toward H-rich 
ferritins, especially in the hemisphere in which both hypoxic and 
ischemic insult was applied (Cheepsunthorn et al., 2001). In another 
ischemic-reperfusion model of the rat brain, induction of both ferritin 
H and L mRNAs occurred in the ischemic insult hemisphere. Protein 
levels, determined by immunohistochemistry, parallelly rises in 
mRNA; surprisingly, although overall induction of H and L mRNA 
was equal, the distribution of H and L ferritin RNA as determined by 
in situ hybridization of rat brains was completely different ( Chi et 
al., 2000). Ferritin changes in hypoxia are at least in part mediated by 
altered regulation of the IRP proteins. IRP1 binding activity 
decreased under hypoxic conditions in rat hepatoma cells (Hanson 
and Leibold, 1998); IRP1 decreased and ferritin levels increased in 
hypoxic mouse macrophages (Kuriyama et al., 2001). In contrast, 
IRP2 activity was found to increase under similar conditions (Toth et 
al., 1999). The period of reperfusion after ischemia is thought to be a 
critical period during which oxidant damage is maximal in many 
tissues, including heart, brain, and other organs. During post-
ischemic reoxygenation of rat liver, early ferritin degradation was 
counteracted by enhanced ferritin transcription and concomitant IRP 
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down-regulation. It was suggested that this might act to re-establish 
ferritin levels and limit reperfusion damage (Tacchini et al., 1997). 
Similarly, in a model of transient surgically-induced segmental 
intestinal ischemia/reperfusion in rats, cytosolic ferritin RNA and 
protein decreased after 3 and 6 hours of reperfusion. By 12 hours, 
ferritin mRNA but not protein had increased to higher than normal 
levels. Ferritin appeared to be regulated both pre-translationally and 
translationally in response to ischemia reperfusion (Yeh et al., 1998). 
Consistent with these findings, reoxygenation was found to induce 
IRP1 in a hepatoma cell line (Hanson and Leibold, 1998) (fig. 8). 
 
3.4 How would hypoxia regulate iron metabolism? 
One proposed mechanism of hypoxic regulation of iron metabolism 
is via hydrogen peroxide (H2O2), possibly from a heme-containing 
oxygen sensor that acts as an IRP2 degradation signal (Hanson et al., 
1999). A decrease in peroxide output from such a sensor during 
hypoxia would thus act to stabilize IRP2. The use of oxygen-derived 
free radicals in the regulation responses appears to be a general 
mechanism for regulating the stability of proteins that mediate 
hypoxic adaptation. 
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Fig. 8. Hypoxia and iron metabolism 
A. Normoxic Cell. This cell is well oxygenated, and the oxygen sensor is 
saturated. This may lead to generation of H2O2, which is known to facilitate 
degradation of HIF-1α and IRP-2. 
B. Hypoxic Cell. This cell is hypoxic is signalled by the oxygen sensor, 
again possibly by a decrease in H2O2 concentration. HIF-1α is stabilized 
and after heterodimerizing with HIF-1β, HIF-1 translocates into the 
nucleus, where it binds to the hypoxia response element (HRE) upstream of 
a multitude of genes, including TfR and Tf. IRP2 is also stabilized and 
activated. 
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For example, hypoxia-induced stabilization of HIF- 1α protein is 
blocked in the presence of H2O2 (Fandrey et al., 1994), suggesting that 
hypoxia-induced changes in the level of this reactive oxygen species 
may involved in HIF-1 activation (Hanson et al., 1999). HIF- 1α 
subunits are targeted for rapid degradation in normoxic cells by a 
proteosomal mechanism operating on an internal oxygen-dependent 
degradation domain (ODD) (Huang et al., 1998). Under hypoxic 
conditions, IRP2 stability would depend on the relative cytosolic 
concentrations of the Fe2+ and H2O2. The Fe2+ concentration may be 
high enough to inactivate the RNA binding activity of IRP1 and 
convert it to its aconitase form, but because of the simultaneous 
decrease in H2O2, the concentration may not be sufficient to signal 
the degradation of IRP2. Data suggest that pVHL might be required 
for oxygen-dependent HIF 1  degradation. The ability of pVHL to 
degrade HIF1 appears to be iron-dependent. Treatment with iron 
chelators prevented the association of pVHL with HIF1, suggesting 
that iron may be necessary for the interaction of pVHL with HIF1 
(Maxwell et al., 1999). Leibold and co-workers (Hanson et al., 1999) 
have suggested four analogies between hypoxic regulation of  HIF-
1α  and IRP2: i) Both proteins accumulate during hypoxia by post-
translational mechanisms involving increased protein stability; ii) 
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CoCl2 stimulates the accumulation of both IRP2 and HIF-1α, perhaps 
by inactivating a heme-containing O2 sensor; iii) iron chelator 
elevated the protein levels of both IRP2 and HIF- 1α; iiii) the 
activation of IRP2 and HIF- 1α by hypoxia and CoCl2 occurs in all cell 
types, suggesting a global mechanism. 
Clearly, the similarities between iron and oxygen metabolism 
suggest that iron and oxygen regulate overlapping cellular activities. 
Both iron depletion and hypoxia ultimately compromise cellular ATP 
generation by curtailing oxidative phosphorylation. In the iron-
depleted cell, oxidative phosphorylation is arrested because this 
process depends on many enzymes containing iron-sulfur clusters. In 
the hypoxic cell oxidative phosphorylation is arrested due to 
substrate (oxygen) deficiency. It appears that the common cellular 
responses to iron depletion and oxygen depletion may be ways for 
cell to compensate for its ATP-deprived status. In iron depletion, the 
cell compensates in two ways. First, to restore the free iron available 
for essential cellular processes, the cell tries to increase its iron 
uptake and decrease its iron storage. Second, while the intracellular 
iron is being replenished, the cell tries to find other means of 
generating ATP. To this end, iron-depleted cells upregulate glycolitic 
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enzymes and glucose transporters via a HIF1-dependent pathway. 
Similarly, in the case of hypoxia, the cell compensates for ATP-
depletion by increasing glycolysis. Here, the hypoxic stimulus causes 
the stabilization of HIF-1α, ultimately resulting in transcriptional up-
regulation of glycolitic enzymes and glucose transporters. 
Augmenting ATP generation may be one important mechanism by 
which iron chelators could prevent neuronal injury during hypoxic-
ischemic insults. 
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4. MATERIALS AND METHODS 
 
4.1 Animals  
Female Wistar rats (Charles River, Calco, Lecco, Italy) were housed 
in diurnal lighting conditions (12 h darkness and 12 h light) and 
fasted overnight but allowed free access to water before the 
experiment. Experiments were performed according to international 
guidelines for animal research and the experimental protocol was 
approved by the Animal Care Committee of the University of Naples 
“Federico II”. 
 
4.2 Primary cortical neuronal cultures   
Cortical neurons were obtained from brains of 15–16-day-old Wistar 
rat embryos (Scorziello et al., 2001). Briefly, the rats were 
anesthetized and then decapitated to minimize the animals' pain and 
distress. Dissection and dissociation were performed in Ca2+/Mg2+-
free phosphate buffered saline (PBS) containing glucose (30 mM). 
Tissues were incubated with papain for 10 min at 37°C and 
dissociated by trituration in Earle’s balanced salt solution (EBSS) 
containing DNase, bovine serum albumin (BSA) and ovomucoid. 
Cells were plated at a concentration of 15x106 on 100-mm plastic 
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Petri dishes precoated with poly-D-lysine (20 µg/mL) in Ham’s F12 
nutrient mixture/Eagle’s minimal essential medium containing 
glucose (1:1), supplemented with 5% of deactivated fetal calf serum 
(FCS) and 5% of deactivated horse serum (HS), L-glutamine (2 mM) 
and penicillin (50 units/mL) and streptomycin (50 µg/mL). Cytosine 
arabinoside (arabinoside-C) (10 µM) was added within 48 h of 
plating to prevent the growth of non-neuronal cells. Neurons were 
cultured at 37°C in a humidified 5% CO2 atmosphere with medium 
replenishment after 6 days, and used after 11 days of culture in all 
experiments.  
 
4.3 Primary glial cell cultures  
Cultures of cortical type-1 astrocytes were obtained as described 
elsewhere (McCarthy and de Vellis, 1980). In brief, 2–3-day-old 
Wistar rats were decapitated, the brains were removed under aseptic 
conditions and placed in PBS containing 100 units/mL penicillin and 
100 µg/mL of streptomycin. Under a stereomicroscope, cortices were 
dissected, the meninges were carefully removed, and the tissues 
were cut into small fragments, digested with trypsin at 37°C for 20 
min., and mechanically dissociated in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 100 units/mL of penicillin and 100 
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µg/mL of streptomycin, 10% FCS and 2 mM glutamine. The medium 
was changed after 24 h and then twice a week. Once confluent, the 
cultures were shaken vigorously to remove non-adherent cells and 
sub-cultured 1:3. The cells were then mechanically purified and sub 
cultured once again 1:4 before the experiments were performed. This 
protocol produced cultures in which  95% of cells were positive to 
glial fibrillary acid protein.  
 
4.4 Glioma cells  
Rat glioma cells (C6 line) were grown in DMEM containing 4.5 g/L 
glucose and supplemented with 10% fetal bovine serum (FBS), L-
glutamine (2 mM), penicillin (100 units/mL) and streptomycin (100 
µg/mL). For iron repletion-depletion experiments, cells were treated 
with 50 µg/mL ferric ammonium citrate (FAC) as a source of Fe ions 
or with 100 µM desferrioxamine (Desferal, Novartis, Origgio, Varese, 
Italy) for 18 h. 
 
4.5 Combined oxygen and glucose deprivation and reoxygenation  
Cortical neurons, type-1 astrocytes and C6 glioma cells were exposed 
to oxygen and glucose deprivation (OGD) for various times 
according to a previously reported protocol (Goldberg and Choi, 
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1993). Briefly, the culture medium was replaced with deoxygenated 
(saturated for 20 min. with 95% N2 and 5% CO2), glucose-free Earle’s 
balanced salt solution containing NaCl 116 mM, KCl 5.4 mM, MgSO4 
0.8 mM, NaHCO3 26.2 mM, NaH2PO4 1 mM, CaCl2 1.8 mM, glycine 
0.01 mM and 0.001 w/v phenol red. Cultures were then placed in an 
humidified 37°C incubator within an anaerobic chamber (Billups-
Rothenberg, Inc., Del Mar, CA) containing a gas mixture of 95% N2 
and 5% CO2. The final oxygen concentration in the medium in these 
experimental conditions, measured by oxygen-sensitive electrode 
(OxyLite 2000, Oxford Optronix, Oxford, UK), was 5 mm Hg. 
Reoxygenation (Reoxy) was achieved by replacing the OGD medium 
with oxygenated regular medium containing glucose and returning 
cultures to normoxic conditions (37°C in a humidified 5% CO2 
atmosphere) for various times. 
 
4.6 Permanent middle cerebral artery occlusion (pMCAO) and 
identification of the ischemic area. 
The pMCAO procedure is described elsewhere (Tortiglione et al., 
2002). Briefly, animals were anesthetized intraperitoneally with 
chloral hydrate (400 mg/kg). The left temporoparietal region of the 
head was shaved and a 2 cm incision was made vertically between 
                                                                                                       
 
 61 
the orbit and the ear. Under an operating stereomicroscope (Nikon 
SMZ800, Florence, Italy), an incision was made dividing the 
temporal muscle, and the left lateral aspect of the skull was then 
exposed by reflecting the temporal muscle surrounding soft tissue. 
An opening (diameter =2 mm) was made with a high-speed 
microdrill through the outer surface of the semitranslucent skull, just 
over the visibly identified middle cerebral artery. A saline solution 
was applied to the area to prevent heat injury. Using a pair of fine 
forceps, the inner layer of the skull was removed and the dura and 
arachnoid were opened. The pMCAO was achieved by 
electrocoagulation with a bipolar electrocauterizer (Diatermo MB122, 
G.I.M.A., Milan, Italy) without damaging the brain surface.  
At various times after pMCAO, animals were decapitated and the 
brains removed. Sham-operated controls underwent surgical 
procedures except for the electrocoagulation of the middle cerebral 
artery. The brain was placed on dry-ice and the coronal sections were 
cut with a vibratome (Campden Instrument, 752M, London, UK) 
beginning at 1 mm posterior to the anterior pole. Coronal slices 0.5- 
and 2-mm thick were alternately cut. The 0.5-mm slices, stained in 
2% triphenyltetrazolium chloride-saline solution, were used to 
identify the ischemic core. The 2-mm slices were used to dissect the 
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ischemic core, identified by triphenyltetrazolium chloride in the 
previous adjacent slice, and the non-ischemic surrounding area. The 
contralateral hemisphere was processed in the same manner. After 
surgical removal, the samples were immediately frozen in liquid 
nitrogen and kept at –80°C until analysis. 
 
4.7 Preparation of cytosolic and mitochondrial extracts  
After OGD and OGD/Reoxy exposure cortical neurons, type-1 
astrocytes and C6  glioma cells were washed and scraped off with 
PBS containing 1 mM EDTA. To obtain cytosolic extracts for 
electrophoretic mobility shift assay (EMSA) and ferritin Western blot 
analysis, cells were treated with lysis buffer containing 10 mM 
HEPES, pH 7.5, 3 mM MgCl2, 40 mM KCl, 5% (v/v) glycerol, 1 mM 
dithiothreitol (DTT), 0.2% (v/v) Nonidet P-40 (NP-40) and protease 
inhibitor tablet (Roche, Mannheim, Germany)  at 4°C. Cell debris and 
nuclei were pelleted by centrifugation at 15,000 g for 10 min. at 4°C 
and supernatants were stored at –80°C. For Western blot analysis of 
cytochrome c and caspase-3, cells were collected by scraping and 
low-speed centrifugation. Cell pellets were lysed at 4°C for 1 h in a 
buffer containing 10 mM KCl, 1.5 mM MgCl2, 20 mM HEPES, pH 7.5, 
1 mM EGTA, 1 mM EDTA, 1 mM DTT, 0.1 mM 
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phenylmethylsulphonyl fluoride and proteases inhibitors tablets 
(Roche). The mitochondrial-containing fraction was obtained by 
centrifugation at 16,000 g for 25 min. Cytosolic extracts 
mitochondria-free were obtained by centrifugation of supernatants at 
100,000 g for 30 min. in a Beckman L8-70 ultracentrifuge. The protein 
concentration was determined by the Bio-Rad protein assay 
according to the supplier's manual (Bio-Rad, Milan, Italy).  
 
4.8 Electrophoretic mobility-shift assay (EMSA)  
Plasmid pSPT-fer, containing the sequence corresponding to the IRE 
of the H-chain of human ferritin, linearized at the Bam HI site, was 
transcribed in vitro with T7 RNA polymerase (Promega). The 
transcriptional reaction was performed at 38.5 °C  for 1 h with 200 ng 
of plasmid in the presence of 50 µCi of [α-32P] CTP (800 Ci/mM) 
(Amersham Biosciences) and 0.5 mM ATP, GTP and UTP (Promega), 
in 20 µl reaction volume (Festa et al., 2000a).  The DNA template was 
digested with 10 units of RNase-free DNase I for 10 min at 37 °C. 
Free nucleotides were removed on Sephadex G-50 column 
(Boehringer- Mannheim). For RNA-protein band-shift analysis, 
cytosolic extracts (5 µg) were incubated for 30 min. at room 
temperature with 0.2 ng of in-vitro transcribed 
32P-labeled IRE RNA. 
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The reaction was performed in buffer containing 10 mM HEPES, pH 
7.5, 3 mM MgCl2, 40 mM KCl, 5% (v/v) glycerol, 1 mM DTT and 
0.07% (v/v) NP-40, in a final volume of 20 µL. To recover total IRP1 
binding activity, cytosolic extracts were pre-incubated for 10 min 
with 2-mercaptoethanol at a 2% (v/v) final concentration, before the 
addition of 32P-labeled IRE RNA. IRP2 activity was differentiated by 
super-shift assay incubating cytosolic extracts with a goat polyclonal 
anti-IRP2 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA) 
for 45 min. at room temperature before electrophoresis. Unbound 
RNA was digested for 10 min. with 1 unit of RNase T1 (Roche) and 
non specific RNA-protein interactions were displaced by the 
addition of 5 mg/mL heparin for 10 min. RNA-protein complexes 
were separated on 6% non denaturing polyacrylamide gel for 2 h at 
200 V. After electrophoresis, the gel was dried and autoradiographed 
at –80°C. The IRP-IRE complexes were quantified with a GS-700 
imaging densitometer and/or with a GS-505 molecular imager 
system (Bio-Rad). The results are expressed as the percentage of IRP 
binding activity versus 2-mercaptoethanol-treated samples. 
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4.9 Western blot analysis 
Samples containing 50 µg of proteins were denatured, separated on a 
12% (for ferritin) or 15% (for cytochrome c and caspase-3) SDS-
polyacrylamide gel and electro-transferred onto a nitrocellulose 
membrane (Amersham Biosciences, Little Chalfont, 
Buckinghamshire, UK) using a Bio-Rad Transblot. Proteins were 
visualized on the filters by reversible staining with Ponceau-S 
solution (Sigma) and destained in PBS.  Membranes were blocked at 
4°C in milk buffer (1X PBS, 10% (w/v) non fat dry milk, 0.1 % (v/v) 
Triton X-100) and then incubated for 3 h at room temperature with 
1:250 sheep polyclonal antibody to human ferritin (Biodesign 
International, Saco, Maine), 1:1000 mouse monoclonal anti-
cytochrome c antibody (Biosource International, Camarillo, CA) or 
1:1500 rabbit polyclonal anti-caspase-3/CPP32 antibody 
(Transduction Laboratories, Lexington, KY). Subsequently, the 
membranes were incubated for 90 min. at room temperature with 
donkey peroxidase-conjugated anti-sheep IgG for ferritin 
determination (Biodesign International) and with sheep peroxidase-
conjugated anti-mouse and anti-rabbit IgG for cytochrome c and 
caspase-3/CPP32 determination (Amersham Biosciences). The 
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resulting complexes were visualized using chemoluminescence 
Western blotting detection reagents (ECL, Supersignal West Pico, 
Pierce, Rockford, IL). The optical density of the bands was 
determined by a GS-700 imaging densitometer and/or a gel image 
analysis system (Chemi Doc Imaging System, Bio-Rad). 
Normalization of results was ensured by incubating the 
nitrocellulose membrane in parallel with the β-actin antibody. 
 
4.10 Metabolic labeling with 35S-methionine/cysteine and 
immunoprecipitation 
Cells were pre-incubated for 30 min. at 37°C in a methionine-
cysteine-free medium. The medium was removed and the cells were 
labeled with 80 µCi/mL Promix L-[35S]-label (Amersham 
Biosciences) in the appropriate methionine-cysteine-free medium for 
3 h during normoxic, OGD or OGD/reoxygenation conditions. Cells 
were washed three times with PBS and lysed in buffer containing 50 
mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100 and 
protease inhibitor tablet (Roche). Aliquots of cytosolic lysates from 
neurons containing 500 µg of proteins or from C6 cells and from 
cortical type-1 astrocytes containing 850 µg of proteins were cleared 
with protein G PLUS-Agarose (Santa Cruz). Then 5 µg of anti-ferritin 
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antibody, previously conjugated with 30 µL of protein G PLUS-
Agarose, were added to the lysates and incubated overnight at 4°C. 
The protein-agarose beads were pelleted, washed three times with 
cold lysis buffer and boiled with SDS loading buffer. 
Immunoprecipitated proteins were resolved by using 12% SDS-
PAGE. After electrophoresis the gel was treated with Amplify 
(Amersham Biosciences) for 30 min., fixed, dried and then visualized 
by autoradiography. Normalization of the incorporation of 35S-
methionine/cysteine into total proteins was made by measuring 
trichloroacetic precipitable radioactive counts or protein content.  
 
4.11 RNA extraction and Northern blot analysis 
After OGD and OGD/Reoxy treatments, total cellular RNA was 
isolated from cells by the TRIzol reagent (Invitrogen Life 
Technologies, Carlsbad, CA) extraction method. The TRIzol reagent 
is a ready-to-use  for the isolation of total RNA from cells. The 
reagent, a mono-phasic solution of phenol and guanidine 
isothiocyanate, is an improvement to the single step RNA isolation 
method developed by Chomczynski (Chomczynski et al., 1987). 
Briefly, cells grown in monolayer were lysed directly in culture dish 
by adding 1 mL of TRIzol reagent to a 3.5 cm diameter dish, and 
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passing the cell lysate several times through a pipette. The amount of 
TRIzol reagent was based on the area of the culture dish (1 mL per 
cm2). The homogenized samples were incubated in tube for 5 min at 
room temperature to permit the complete dissociation of 
nucleoprotein complexes. 200 µL of chloroform were added to each 
sample and tubes were shaked vigorously for 15 seconds and then 
incubated for 3 min at room temperature. Successively, samples were 
centrifuged at 12,000 x g for 15 min at 4°C. Following centrifugation, 
the mixture separates into a lower red, phenol-chloroform phase, an 
interphase, and a colorless upper aqueous phase. RNA remains 
exclusively in the aqueous phase (about 60% of the volume of TRIzol 
reagent used). The aqueous phase was transferred to a fresh tube and 
RNA was precipitated by mixing with 500 µL of isopropyl alcohol. 
After centrifugation at 12,000 x g at 4°C for 15 min, RNA precipitate 
forms a gel-like pellet on the side and bottom of the tube. 
For Northern blots 10 µg of total RNA were fractionated on a 1.5% 
agarose denaturing formaldehyde gel in MOPS buffer. RNA was 
transferred by blotting in 20X SSC (1X SSC, 0.15 M NaCl, 0.015 M Na-
citrate) , pH 7.0, to Hybond-N filters (Amersham Biosciences). The 
hybridization was performed for 18 h at 65°C in 0.5 M sodium 
phosphate buffer, pH 7.2, 1 mM EDTA, pH 8.0, 7% (w/v) SDS. The 
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filters were washed in 0.05 M sodium phosphate buffer pH 7.2, 1% 
(w/v) SDS at 65°C and autoradiographed at –80 °C. A cDNA 
fragment corresponding to human cDNA for H-ferritin was 32P-
radiolabelled using the random priming method (TaKaRa 
Biomedicals, Otsu, Shiga, Japan). 100 ng of template DNA and 2 µL 
of random primer were combined in a microcentrifuge tube, and 
sterile distilled water was added to a final volume of 14 µL. The mix 
was heated at 95°C for 3 min and then cooled on ice for 5 min. Then 
2.5 µL of 10 X buffer, 2.5 µL of the dNTP mixture and 5 µL (50 µCi) of 
32P-labelled dATP ([α-32P] dATP, 3000 Ci/mM, Amersham 
Biosciences) were added to the mixture. Successively, 1 µL of Exo-
free Klenow fragment was added (total final volume 25 µL) and the 
mix was incubated at 37°C for 1 h. The polymerase reaction was 
stopped by adding 0.5 µL EDTA 0.5 M and probes were purified on a 
Bio-Spin 30 chromatography column (Bio-Rad).  The β-actin probe 
was used to standardize the amounts of mRNA in each lane.  
 
4.12 Cell viability assay 
Cell viability was assessed by measuring the level of mitochondrial 
dehydrogenase activity using 3-(4,5-dimethyl-2-thiazolyl)-2,5-
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diphenyl-2H-tetrazolium bromide (MTT) as substrate (Hansen et al,. 
1989). The assay was based on the redox ability of living 
mitochondria to convert dissolved MTT into insoluble formazan. 
Briefly, after OGD and OGD/Reoxy, the medium was removed and 
the cells were incubated in 1 mL of MTT solution (0.5 mg/mL) for 1 
h in a humidified 5% CO2 incubator at 37°C. The incubation was  
stopped by removing the MTT solution and adding 1 mL of DMSO 
to solubilize the formazan. The absorbance was monitored at 540 nm 
by using a Perkin-Elmer LS 55 Luminescence Spectrometer (Perkin-
Elmer Ltd, Beaconsfield, UK). The data are expressed as the 
percentage of cell viability to control cultures.  
 
4.13 Lipid peroxidation assay 
Lipid peroxidation products from cells were measured by the 
thiobarbituric acid colorimetric assay (Esterbauer and Cheeseman, 
1990). Briefly, after OGD and OGD/Reoxy cells were washed and 
collected in PBS Ca2+/Mg2+ free medium containing 1 mM EDTA and 
1.13 mM butylated hydroxytoluene (BHT). Cells were broken up by 
means of sonicator. Trichloroacetic acid, 10% (w/v), was added to 
cellular lysate and, after centrifugation at 1,000 g for 10 min., the 
supernatant was collected and incubated with 0.5 % (w/v) 
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thiobarbituric acid at 80°C for 30 min. After cooling, malondialdehyde 
(MDA) formation was recorded (A530 nm and A550 nm) in a Perkin 
Elmer LS-55 spectrofluorimeter. Samples were scaled for protein 
concentration determined by the Bio-Rad protein assay and a standard 
curve of MDA was used to quantify the MDA levels formed during the 
experiments. The results are presented as percentage of MDA 
production versus a control obtained in untreated cultures.  
 
4.14 Apoferritin treatment of cortical neurons 
 
Primary cortical neurons, cultured in Ham’s F12 nutrient 
mixture/Eagle’s minimal essential medium as above described, were 
treated for 18 h with 0.3 mg/mL apoferritin (Sigma-Aldrich, St Louis, 
MO) that is easily pinocytosed by the cell (Balla et al., 1992; Festa et al,. 
2000b). After treatment cells were washed, culture medium was 
replaced with deoxygenated glucose-free Earle’s balanced salt 
solution, and then were exposed to OGD and OGD/reoxygenation. 
Lipid peroxidation products from cells were measured as above 
described. The intracellular ferritin content in cytosolic extract was 
determined using a fluorimetric enzyme immunoassay system 
according to the supplier’s manual (Enzymum test, Roche). The results 
are expressed as ng of ferritin/mg of cell protein. 
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4.15 Statistical analysis  
The densitometric data of EMSA, Western blot, Northern blot, 
biosynthesis bands and neurons apoferritin treatment are reported as 
means + SEM. Statistical significance among the means was 
determined by the ANOVA followed by the Newman-Keuls test. A p 
value < 0.05 was considered statistically significant.  
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5. RESULTS 
 
5.1 IRP RNA-binding activity in cortical neurons and in glial cells 
after OGD 
To determine the effects of OGD on IRP RNA-binding activity, we 
exposed cortical neurons from rat embryos, primary cultures of rat 
astrocytes type-1 and C6 rat glioma cells to normoxic and hypoxic 
conditions for 0 to 5 h and then we measured the IRP RNA-binding 
activity by RNA band-shift assay. As shown in Fig. 9 in cortical 
neurons, OGD significantly enhanced IRP1 RNA-binding activity. 
This effect appeared after only 30 min. of OGD exposure (22% 
increase vs control), peaked at 3 h  (98% of increase vs control) and 
persisted up to 5 and 12 h (data not shown). To determine the total 
amount of IRP1 RNA-binding activity, β-mercaptoethanol was 
added to the binding reactions before the addition of 32P-labeled IRE 
probe. β-mercaptoethanol reveals “latent” IRP1 RNA-binding 
activity thus giving the total amount (100% of IRE-binding) of IRP1 
activity (Hentze et al., 1989). Addition of β-mercaptoethanol to 
neuron extracts did not enhance further OGD-stimulated IRP1 RNA-
binding activity (Fig. 9A, lanes 6-10), suggesting that OGD promoted 
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Fig. 9. IRP1 and IRP2 RNA-binding activity in rat cerebral cells during 
OGD  
(A) RNA band-shift assay performed in the absence (lanes 1-5) or presence 
(lanes 6-10)  of 2% β-mercaptoethanol (2-ME). Cortical neurons, astrocytes 
and C6 glioma cells were grown under normoxic conditions (lane 1) or 
hypoxic conditions (lanes 2–5). RNA-protein complexes were separated on 
non-denaturing 6% polyacrylamide gels and revealed by autoradiography. 
(B) IRP1-RNA complexes were quantified by densitometric and/or 
PhosphorImager analysis. The results of lanes 1–5 were plotted as percent 
of respective controls treated with 2-ME. Lane 6 of each panel represents 
100% of IRP1 RNA-binding activity. * p<0.05 compared with controls. 
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maximal IRP1-RNA association without altering the IRP1 protein 
content.  
Differently, type-1 primary astrocytes responded to OGD with a 
decrease (42% decrease vs control) in IRP1 RNA-binding activity 
after 30 min. and this reduction persisted up to 5 h. Addition of β-
mercaptoethanol determined an increase in IRP1 RNA-binding 
activity in all samples (Fig. 9 A, lanes 6-10), suggesting that the OGD-
induced inactivation of IRP1 was not due to a variation in IRP1 
protein levels nor to modifications that irreversibly inactivated IRP1 
RNA-binding.  
Exposure of C6 glioma cells to OGD produced a similar rapid 
decrease (38% decrease vs control) of IRP1 RNA-binding after 30 
min., reaching a maximum decrease of 60% vs control at 3 h. This 
reduction also persisted for 5 h. Concomitant to the IRP1 RNA-
binding decrease, there was a slight OGD-dependent increase in 
IRP2 RNA-binding activity. It should be noted that 2- 
mercaptoethanol treatment decreases IRP2 activity in both glial cells. 
This phenomenon could be explained by the sensibility of IRP2 to 
redox influence. In fact, routine in vitro treatment of cell extracts with 
2% 2-mercaptoethanol, useful to maximally activate IRP1 binding 
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activity, results in underestimation of IRP2 activity (Bouton et al., 
1997). 
 
5.2 Response of IRP2  to iron concentration during OGD 
To verify that the faster migrating band was IRP2, we treated C6 cells 
for 18 h with 50 µg/mL iron salt ferric ammonium citrate (FAC) or 
with 100 µM of the potent iron chelator desferrioxamine (DFX), and 
then exposed the cells to OGD. Under normoxic conditions the IRP2-
IRE complex was not present in either the control or iron-treated cells 
but appeared in iron-depleted cells (Fig. 10, lanes 1–3). This is in 
accordance with iron regulation of  IRP2 (Iwai et al., 1998). In cells 
exposed to OGD, the faster migrating band disappeared upon 
exposure to FAC (lane 5) and reappeared upon exposure to DFX 
(lane 6), indicating that this band corresponded to the IRP2-IRE 
complex. These results were confirmed by super-shift assay using 
IRP2-specific antibody (Fig. 10, right side). 
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Fig. 10. Response of IRPs to intracellular iron concentration during OGD 
Rat glioma C6 cells were exposed to ferric ammonium citrate (FAC) for 18 
h, desferrioxamine (DFX) for 18 h, OGD for 3 h. Cytosolic extracts from 
cells exposed to normoxic conditions (lanes 1–3) or to 3 h of OGD (lanes 4-
6) were  subjected to RNA band-shift assay. Experiments were performed 
in the absence (lanes 1-6) or presence (lanes 7–12) of 2% β-mercaptoethanol 
(2-ME). IRP2 activity was also identified by super-shift assay using a goat 
polyclonal anti-IRP2 antibody (right side).  
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5.3 IRP RNA-binding activity during OGD followed by 
reoxygenation 
It has been reported that the reoxygenation reverte the hypoxic 
modulation of IRP RNA-binding activity in several cell types 
(Tacchini et al., 1997; Hanson and Leibold, 1998; Schneider and 
Leibold, 2003). To test whether reoxygenation reverted IRP 
modulation by OGD also in cortical neurons and glial cells, cells 
were exposed to OGD for 3 h and reoxygenated for 3 and 24 h after 
which IRP RNA-binding activity was measured and results are 
depicted in Fig. 11. In cortical neurons, reoxygenation gradually 
reverted OGD-induced IRP1 activation, and baseline levels were 
reached within 24 h of treatment. On the contrary, in C6 glioma cells 
IRP1-RNA binding activity increased after 3 h of reoxygenation, and 
reached control level after 24 h. IRP2 RNA-binding became 
undetectable after 24 h of reoxygenation, as occurred in cells cultured 
in normoxic conditions. Similarly, in astrocytes IRP1 RNA-binding 
activity was completely restored after 24 h of reoxygenation, 
although there was no significant variation after 3 h of 
reoxygenation.  
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Fig. 11. IRP1 and IRP2 RNA-binding activity in rat cerebral cells during 
reoxygenation  
(A) Cortical neurons, astrocytes and C6 rat glioma cells were exposed for 3 
h to OGD (lane 2 of the respective panels) followed by re-exposure to 
normoxia (Reoxy), for 3 and 24 h (lanes 3 and 4). Cytosolic extracts were 
incubated with an excess of 32P-labeled IRE probe in the absence (lanes 1–4) 
or presence (lanes 5–8) of 2% β-mercaptoethanol (2-ME). (B) IRP1-RNA 
complexes were quantified by densitometric and/or PhosphorImager 
analysis and the results plotted as percent of controls treated with 2-ME 
(lane 5 of each panel, which corresponds to 100% of IRP1 RNA-binding 
activity). * p<0.05 compared with control; ** p<0.05 compared with 3 h of 
OGD. 
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5.4 Effects of OGD and OGD/reoxygenation on ferritin expression  
To evaluate the combined effect of OGD and following 
reoxygenation on ferritin expression in cortical neuronal and glial 
cells, we determined ferritin protein levels by Western blot analysis 
after 3 h of OGD and after OGD followed by 3 and 24 h of 
reoxygenation. In cortical neurons ferritin content resulted 
unchanged after 3 h of OGD and after 3 h of reoxygenation, while 
there was a significant 1.6-fold increase in the late phase of 
reoxygenation (24 h) (Fig. 12). On the contrary, after 3 h of OGD 
ferritin levels significantly increased by about 2.0- and 1.8-fold in 
astrocytes and C6 glioma cells, respectively. In C6 cells the exposure 
to reoxygenation for 3 h determined a decrease in ferritin content, 
which however was higher than control. After 24 h of reoxygenation, 
ferritin amount decreased to baseline levels. Similarly, in astrocytes 
ferritin content decreased during reoxygenation (33% decrease vs 
OGD after 24 h reoxygenation).  
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Fig. 12. Effects of OGD and OGD/Reoxy on cellular ferritin levels 
(A) Rat cortical neurons, type-1 astrocytes and C6 glioma cells were 
exposed for 3 h to OGD followed by re-exposure to normoxia for 3 and 24 h  
(Reoxy). Equal amounts of cytosolic lysates of proteins were fractionated 
by 12% SDS-PAGE and subjected to Western blot analysis (B) The bands 
corresponding to ferritin were quantified by densitometric analysis and 
plotted as arbitrary units. The anti-β-actin antibody was used to 
standardize the amounts of proteins in each lane. # p< 0.05  as compared to 
other experimental groups; * p< 0.05 as compared to control group;  ** p< 
0.05 as compared  to 3 h of OGD. 
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Fig. 13. Ferritin synthesis during OGD and OGD/Reoxy  
(A) Cortical neurons, astrocytes and C6 glioma cells were exposed to OGD 
(3 h) followed by reoxygenation (Reoxy) for 3 and 24 h. Cells were labeled 
with 35S-Met/Cys. Cell extracts were immunoprecipitated and proteins 
subjected to SDS-PAGE analysis and autoradiography. (B) The bands 
corresponding to ferritin were quantified by densitometric analysis and 
plotted as arbitrary units. * p<0.05 compared with control; ** p<0.05 
compared with 3 hr of OGD. 
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5.5 Effects of OGD and OGD/reoxygenation on ferritin 
biosynthesis 
We evaluated ferritin biosynthesis by immunoprecipitation of 35S-
labelling in cortical neurons, type-1 astrocytes and C6 cells exposed 
to OGD and OGD/reoxygenation (Fig. 13). In type-1 astrocytes the  
rate of 35S-methionine/cysteine incorporation into ferritin enhanced 
of about 2.6-fold during the OGD and progressively increased of  
about 4.6-fold during the subsequent reoxygenation phases. In C6 
cells ferritin biosynthesis was increased of about 2.6-fold during 3 h 
of OGD. The subsequent 3 h of reoxygenation increased ferritin 
biosynthesis by about 5-fold,  and after 24 h of reoxygenation ferritin 
returned to control levels. Similar experiments with cortical neurons 
showed a consistent increase in ferritin biosynthesis only during the 
reoxygenation phase, i.e., a 6- and 11-times increase after 3 and 24 h,  
respectively. 
 
5.6 Analysis of H-ferritin mRNA levels after OGD and 
OGD/reoxygenation 
To assess whether the improved ferritin level observed during OGD 
and OGD/reoxygenation might result from transcriptional control, 
we analyzed by Northern blot the steady-state levels of H-ferritin 
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mRNA (Fig. 14).  In type-1 astrocytes the level of H-ferritin mRNA 
resulted slightly decreased after the OGD exposure and 
progressively increased during the reoxygenation phases (3 and 24 
h). Instead H-ferritin mRNA content remained unchanged in C6 cells 
exposed to OGD and OGD/reoxygenation. Differently, in cortical 
neurons Northern blot analysis showed a significant increase of H-
ferritin mRNA amount (about 2.3-fold) only in the late phase of 
reoxygenation (24 h).  
 
5.7 Effects of OGD and OGD/reoxygenation on lipid peroxidation 
and on cell survival 
To investigate the effects of OGD and OGD/reoxygenation on cell 
survival, we evaluated cell viability by MTT assay, cell membrane 
injury by MDA production, and the induction of apoptotic features 
by cytochrome c release and activated caspase-3 expression 
evaluation. Exposure of cortical neurons to OGD for 3 h induced 
impairment of mitochondrial oxidative capacity (fig. 15) associated 
with increased MDA production (fig.16). When the neurons were 
exposed to OGD/reoxygenation, an enhanced mitochondrial activity 
impairment was associated with a significant increase of lipid 
peroxidation.  
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Fig. 14. Northern blot analysis for H-ferritin mRNA levels  
A) RNA was isolated from cortical neurons, astrocytes and C6 glioma cells 
exposed for 3 h to OGD followed by reoxygenation for 3 and 24 h (Reoxy). 
10 µg of total cellular RNA were hybridized to H-ferritin cDNA 32P-
radiolabeled probe. The β-actin probe was used to standardize the amounts 
of mRNA in each lane.  (B) The bands corresponding to H-ferritin mRNA 
were quantified by densitometric and/or PhosphorImager analysis and 
plotted as arbitrary units. # p< 0.05  as compared to other experimental 
groups; * p< 0.05 as compared to control group;  ** p< 0.05 as compared  to 
3 h of OGD. 
 
C6 glioma cells
C      OGD  Reoxy Reoxy
3h       3h 24h
H-fer
mRNA
0 3 3 24
0
10
20
30
40 #
H-
fe
r 
m
RN
A
de
n
s
ito
m
et
ry
 
(re
la
tiv
e 
O
D/
m
m
2 )
0 3 3 24
0
10
20
30
40
H-
fe
r 
m
RN
A
de
n
s
ito
m
et
ry
 
(re
la
tiv
e 
O
D/
m
m
2 )
Cortical neurons C6 glioma cells
Type-1 astrocytes
A
B
0 3 3 24
0
10
20
30
40
*
*
**
*
H-
fe
r 
m
RN
A
de
n
s
ito
m
et
ry
 
(re
la
tiv
e 
O
D/
m
m
2 )
Type-1 astrocytes
H-fer
mRNA
H-fer
mRNA
β-act
mRNA
β-act
mRNA
β-act
mRNA
C      OGD  Reoxy Reoxy
3h       3h 24h
C     OGD  Reoxy Reoxy
3h       3h 24h
Cortical neurons
OGD (h)   Reoxy (h) OGD (h)   Reoxy (h) OGD (h)   Reoxy (h) 
                                                                                                       
 
 86 
 
 
 
 
 
 
Fig. 15. Effects of OGD and OGD/reoxygenation on survival of cortical 
neurons and glial cells.  
Primary cultures of cortical neurons were exposed to OGD (3 hrs) and to 
OGD/reoxygenation (24 hrs). Cell viability was assessed by measuring the 
level of mitochondrial dehydrogenase activity using 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) as substrate. The 
data are presented as percentage of insoluble formazan production versus a 
control obtained in untreated cultures (left side). * p<0.05 compared with 
untreated cultures. 
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Fig.16. Effects of OGD and OGD/reoxygenation on free radical 
production in cortical neurons and glial cells.  
Primary cultures of cortical neurons and glial cells were exposed OGD and 
OGD/reoxygenation (24 h). Lipid peroxidation was measured by a 
thiobarbituric acid colorimetric assay and the data are presented as 
percentage of MDA production versus a control obtained in untreated 
cultures. * p<0.05 compared with untreated cultures. 
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Exposure of cortical neurons to OGD and to subsequent 
reoxygenation caused the release of cytochrome c into cytosol and 
induced activation of caspase-3, two hallmarks of apoptosis. 
Conversely, OGD and OGD/reoxygenation did not significantly 
modify mitochondrial oxidative capacity or MDA production in 
either astrocytes or glioma cells. No apoptotic features were 
identified in either cell type. In Fig. 17 are showed the results of 
Western blot analysis for cytochrome c release and caspase-3 
cleavage in all cell types analysed. The results are summarized in 
Table 1. 
 
5.8 Effect of exogenous ferritin addition on lipid peroxidation in 
cortical neurons exposed to OGD followed by reoxygenation 
To establish whether the greater vulnerability observed in cortical 
neurons compared to glial cells was related to the delayed increase in 
ferritin biosynthesis occurring during the OGD/reoxygenation 
phase, we exposed cortical neurons to apoferritin which is easily 
pinocytosed by the cell (Balla et al., 1992; Festa et al., 2000b) via 
receptors that have been identified in the CNS (Hulet et al., 2000). 
Then we evaluated ferritin effect on OGD/reoxygenation-induced 
lipid peroxidation. To this aim cortical neurons were pretreated with  
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Fig. 17. Western blot analysis for cytochrome c release and for pro-
caspase-3 cleavage 
Cortical neurons, astrocytes and C6 glioma cells were exposed for 3 h to 
OGD followed by reoxygenation for 24 h (Reoxy). Equal amounts of 
proteins from cytosolic and mitochondrial fractions were electrophoresed 
on 12% SDS-PAGE and subjected to Western blot analysis using 
cytochrome c and caspase-3/CPP32 antisera. Immunocomplexes were 
detected by chemoluminescence. Caspase-3/CPP32 antibody recognizes 
both the 32 kDa unprocessed pro-caspase-3 and the 17 kDa subunit of 
active caspase-3. The anti-β-actin antibody was used to standardize the 
amounts of proteins in each lane.  
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Table 1. Effects of OGD and OGD/reoxygenation on free radical 
production and on survival of cortical neurons and glial cells.  
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apoferritin (0.3 mg/mL) for 18 h, exposed to OGD and 
OGD/reoxygenation Ferritin concentration was determined in 
cytosolic extracts by enzyme immunoassay system and the results 
showed an increased ferritin content in neurons after apoferritin 
treatment compared to control cells (Fig. 18). Preincubation of 
neurons with exogenous apoferritin reduced the lipid peroxidation 
occuring after the OGD/reoxygenation phase of 57% (Fig. 18), thus 
suggesting that the increased intracellular content of the iron-
scavenging ferritin is indeed related to antioxidant cellular defense.  
 
5.9 In vivo cerebral ischemia modulates IRP-RNA binding and 
affects ferritin levels  
 To investigate in vivo the molecular mechanisms governing changes 
in ferritin levels during hypoxia, we used the pMCAO procedure as 
a model of cerebral ischemia. Protein extracts of ischemic core and 
the area surrounding the ischemic core after 3, 6, 9 and 24 hr of 
pMCAO were processed for IRP RNA-binding activity analysis. As 
shown in Fig. 19 A IRP1 activity resulted increased in the ischemic 
core after 3 hr of pMCAO and progressively decreased reaching the 
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Fig. 16. Ferritin effect on lipid peroxidation in cortical neurons 
exposed to OGD followed by reoxygenation 
Cortical neurons were incubated with apoferritin (Apo) for 18 h 
before exposure to OGD (3 h) and then exposed to reoxygenation (24 
h). Cells were lysed, lipid peroxidation was evaluated and the data 
are presented as percentage of MDA production versus untreated 
cultures (left side). * p<0.05 compared with untreated neurons 
exposed to OGD/reoxygenation. Ferritin concentration was 
determined by the enzyme immunoassay system (right side). #  
p<0.05 versus respective controls.  
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baseline levels at 24 hr. On the contrary, IRP1 binding activity was 
unchanged in protein extracts of the area surrounding the ischemic  
core. Addition of β-mercaptoethanol resulted in similar IRP1-binding 
activity in all samples, suggesting that ischemia-mediated changes in 
IRP1 in the brain occurred without changes in IRP1 protein level. 
Ferritin content, evaluated by Western blot, decreased in the 
ischemic core after 24 hr of pMCAO as compared to the contralateral 
area (Fig. 19 B). No changes in ferritin levels were found in the 
extract from the area surrounding the ischemic core. 
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Fig. 19. Effects of in vivo cerebral ischemia on IRPs RNA-binding and 
ferritin levels  
(A) Proteic extracts from ischemic core and penumbra regions of rat brain 
exposed to pMCAO were subjected to RNA band-shift assay using an excess 
of 32P-labeled IRE probe in presence (lanes 6-10) or absence (lanes 1-5) of 2% 
β-mercaptoethanol (2-ME). (B) Equal amounts of proteins from ischemic 
and penumbra rat brain regions were fractionated by 12% SDS-PAGE and 
subjected to Western blot analysis. Ferritin was visualized by 
chemoluminescence Western blotting detection reagents.  
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6. DISCUSSION AND CONCLUSIONS 
 
Perturbations in cellular iron and ferritin are emerging as an 
important element in the pathogenesis of disease. These changes in 
ferritin are important not only in the classic diseases of iron 
acquisition, transport and storage, such as primary hemocromatosis, 
but also in diseases characterized by inflammation, infection, injury, 
and repair. Among these are some of the most common diseases that 
afflict mankind: neurodegenerative diseases such as Parkinson 
disease ( Linert et al, 2000) and Alzheimer disease ( Kondo et al, 1996),  
vascular diseases such as cardiac and neuronal ischemia-reperfusion 
injury (Chi SI et al, 2000) and a variety of premalignant conditions 
and cancers . 
 We demonstrated that oxygen-glucose deprivation followed by 
reoxygenation affects IRP1 activity and ferritin biosynthesis 
differently in cortical neurons and glial cells (Irace et al., 2005) IRP1 
binding activity was significantly decreased in primary cultures of 
type-1 astrocytes and C6 glioma cells during OGD. On the contrary, 
OGD remarkably increased IRP1 binding activity in primary cultures 
of cortical neurons. The experiments with the reducing agent 2-
mercaptoethanol, which maximally activates “latent” IRP1 RNA-
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binding activity, show that the effects were not caused by a change in 
IRP1 protein content during OGD. The evidence that hypoxia did not 
affect IRP1 protein content coincides with data obtained in human 
embryonic kidney cells (Hanson et al., 1999). In addition, IRP2 
binding activity occurred in astrocytes and, at a higher level, in C6 
glioma cells exposed to OGD, but not in cortical neurons. The 
presence of IRP2 in glia-derived cells could be due to the differential 
expression of IRP2 in different cerebral cell types (Leibold et al., 2001) 
or to the developmental status of the cells (Siddappa et al., 2002).  
Moreover, in glial cells OGD had an opposite effect on the IRPs, i.e. it 
decreased IRP1 binding activity and increased IRP2 binding activity. 
The same divergent modulation occurs in epithelial HEK293 cells 
(Hanson et al., 1999; Schneider and Leibold, 2003) and in some 
mammalian tissues (Meyoron-Holtz et al., 2004). The increase of IRP2 
binding activity  during OGD could be due to the accumulation of 
IRP2 protein (Hanson et al., 1999; Schneider and Leibold, 2003) as a 
consequence of an oxygen-dependent decrease in IRP2 
ubiquitination (Hanson et al., 2003). Thus, it appears that oxygen 
tension exerts a relevant, opposite role in the modulation of IRP1 and 
IRP2 binding activity, even if can not be excluded that IRPs may 
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themselves be subjected to not yet identified regulatory mechanisms 
induced by OGD/reoxygenation.  
In C6 glioma cells, intracellular iron can also contribute to IRP1 and 
IRP2 hypoxia-induced regulation. It is generally agreed that iron 
overload and iron depletion exert a regulatory function through IRP1 
[4Fe-4S] cluster assembly/disassembly and IRP2 
degradation/stability (Pantopoulos, 2004). Interestingly,  our results 
in glioma cells show that, when the increase or decrease of iron levels 
inhibit or stimulate IRP1 and IRP2 activity, respectively, the 
subsequent reduction of oxygen tension by OGD did not further 
affect IRP binding activity. This is compatible with the hypothesis 
that iron and oxygen regulate the Fe-S aconitase/IRP1 cluster switch 
from the same site. 
During reoxygenation, the OGD-induced changes in IRPs binding 
activity were reverted and progressively returned to normoxic levels 
in neuronal and glial cells. Restoration of IRPs activity by normoxic 
conditions agrees with reports on non-excitable cells (Tacchini et al. 
1997, 2002; Hanson and Leibold, 1998; Schneider and Leibold, 2003). 
The results obtained during reoxygenation can be ascribed to 
restoration of oxygen level or to production of radical oxygen species 
(ROS) that elicit activation of IRP1 (Hanson and Leibold, 1998).  
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During OGD and reoxygenation phase, the opposite and differential 
modulation of IRPs occurring in neurons and in glial cells, are 
accompanied also by changes in ferritin expression. In fact, in C6 
glial cells steady-state level and synthesis of ferritin increased early 
during OGD, in accordance with the decrease of IRP1 RNA-binding 
activity. The further increase in ferritin biosynthesis observed at 3 h 
of reoxygenation is not reflected in a corresponding increase in the 
protein steady-state levels at this time, suggesting that ferritin half-
life could be decreased during the early phase of reoxygenation. The 
prolonged reoxygenation did not cause a further increase of 
biosynthesis and steady-state levels of ferritin, in accordance with the 
recovery of IRP1 binding activity. In these cells, the transcriptional 
control on ferritin expression does not seem to operate since there 
were no changes in H-ferritin mRNA levels and therefore, ferritin 
expression is regulated by the more rapid post-transcriptional 
mechanism operated by IRPs. 
In type-1 astrocytes transcriptional and post-transcriptional 
mechanisms seem to operate in a different way during OGD and 
OGD/reoxygenation phases in order to maintain high ferritin levels. 
In fact, during OGD H-ferritin mRNA levels were decreased and the 
increased ferritin expression was IRP-dependent. During the early 
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reoxygenation phase ferritin expression seemed to be dependent by a 
coupled transcriptional and post-transcriptional control, since H-
ferritin mRNA was increased and IRP1 binding activity was low. 
Also in this case, it can not be excluded that ferritin half-life could be 
decreased during this phase. During the prolonged reoxygenation 
phase, in accordance with the increased level of H-ferritin mRNA, 
the transcriptional control seemed to be the only operating 
mechanism to maintain high ferritin content, since IRP1 binding 
activity returned to basal levels. 
Conversely, in cortical neurons ferritin expression increased only 
during the late reoxygenation phase when the IRP1 activity returned 
to basal level. However, it should be noted that after 3 hr of 
reoxygenation ferritin synthesis was increased, when protein and 
mRNA steady-state levels  were unchanged, and IRP1 binding 
activity, although in a declining phase, was still elevated. This 
apparent discrepancy between increased ferritin synthesis, a 
sustained IRP-binding activity and no change in mRNA content, can 
be due to the activation of the protein synthesis machinery that more 
efficiently translates the ferritin mRNAs present in the cell. In 
addition, it is possible that the increase in ferritin synthesis cannot be 
detected by the Western blot analysis as consequence of a decreased 
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ferritin half-life during the early reoxygenation phase. The significant 
increase of ferritin levels at 24 h of reoxygenation seems to be mainly 
regulated at transcriptional level since Northern-blot analysis 
demonstrated a marked increase of H-ferritin mRNA at this time. 
This latter result is in agreement with report showing a significant 
induction of ferritin gene transcription following cerebral 
ischemia/reperfusion (Chi et al., 2000). The transcriptional regulation 
of H-ferritin observed during reoxygenation, that implicates an 
increase in relative amount of this subunit, could reflect the need of 
an increased iron storage and is consistent with the concept that cells 
are responding to the stress by increasing the H-ferritin (Theil, 1987).  
Since neurons and glia have a different susceptibility to oxidative 
stress caused by hypoxia/reoxygenation (Rosenblum, 1997), the 
different regulation of ferritin expression may help to explain the 
diverse vulnerability of neurons and glial cells to 
OGD/reoxygenation injury. In fact,  exposure of neurons to 
OGD/reoxygenation determined impairment of mitochondrial 
activity, marked lipid peroxidation and apoptosis. Under the same 
experimental conditions, glial cells did not show any appreciable 
reduction in cell viability, lipid peroxidation or apoptosis. The 
response of neurons can be explained considering that the increased 
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IRP1 binding activity during OGD determines a reduced ferritin 
synthesis and an induction of transferrin receptor expression, which 
could expand the intracellular labile iron pool  (Tacchini et al., 1997) 
and enhance oxidative damage that the delayed ferritin synthesis 
during reoxygenation is unable to counteract. Conversely, in glial 
cells the down-regulation of IRP1 binding activity during the OGD 
could facilitate iron sequestration into ferritin and prevent the 
oxidative damage due to the formation of the higly reactive oxygen 
species. Moreover, the results obtained with exogenously added 
apoferritin to cortical neurons demonstrated that ferritin decreased 
the OGD/reoxygenation-induced lipid peroxidation, thus suggesting 
that ferritin acts as a cytoprotective agent by limiting the ability of 
intracellular iron to generate ROS. Of course, the cytoprotective role 
exerted by exogenous ferritin is appreciable only during the 
reoxygenation phase, when the oxygen availability promotes the 
iron-induced ROS production. Therefore, the earlier ferritin synthesis 
increase observed in glial cells may represent an adaptive response 
to oxidative stress generated by OGD/reoxygenation explaining 
their reduced vulnerability to anoxic insults.  
Interestingly, in the in vivo model of brain ischemia induced by 
pMCAO, there was an early and brief increase in IRP1 binding 
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activity followed by a prolonged reduction in the ischemic core, 
whereas ferritin expression was slightly reduced. Although the 
pMCAO experiments are related to total brain tissue, these findings 
suggest that also in vivo cerebral ischemia alters IRP RNA-binding 
activity and ferritin expression. However, the pMCAO-induced 
changes in the IRP-IRE complex formation were not associated with 
the changes in ferritin levels, thus suggesting that such other 
regulatory events as increased ferritin degradation, could override 
the effects of IRP-IRE interaction to control steady-state ferritin levels 
during prolonged ischemia. 
It is conceivable that besides being directly regulated by IRPs, ferritin 
can be indirectly modulated by other factors activated during 
hypoxia/reoxygenation. In fact, the hypoxia-inducible factor-1 (HIF-
1) that induces the expression of several genes including those 
involved in iron metabolism, i.e., transferrin, transferrin receptor and 
heme oxygenase-1 (Semenza, 2000), may contribute to the regulation 
of iron homeostasis. In fact, under the oxidative stress of 
hypoxia/reperfusion, heme oxygenase-1 is induced and cleaves the 
heme porphyrin ring releasing Fe2+ that in turn may induce ferritin 
expression.  
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In conclusion, the results reported in this thesis demonstrate that 
IRPs RNA-binding activity and ferritin biosynthesis are oppositely 
regulated in cortical and glial cells exposed to an experimental 
condition that mimics brain ischemia. The changes observed may be 
viewed as an adaptive response of the cell to the iron homeostasis 
dysregulation induced by hypoxia/reoxygenation.  
In the light of data on cross-talk between glial and neuronal cells 
(Bezzi et al., 2001) and our results, it is feasible that when neurons 
and glial cells are exposed to hypoxia/reoxygenation, glial cells by 
the early increase in ferritin, which is able to sequester iron, might 
indirectly protect neurons from the metal-induced injury. 
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